


TOGETHER CROWDFUNDING - USE OF PROCEEDS

About Takaro Tech (“Takaro”)

Imagine huge “tablet-like” (i.e. i-Pad) tiles, fitted together in varied configurations. One can step or jump on them and touch them, whether placed on a floor, a table or hung on the wall.

Takaro Tech has developed the innovative Qni™ system: the technology to revolutionize rehabilitation, training, and the gaming markets.

The Qni system utilizes open platform technology that consists of interactive connectable tiles equipped with multi touch sensors and machine learning AI management tools. With a constantly growing repertoire of adaptive activities and games, the Qni system is designed to empower users and caregivers, in rehabilitation, training and gamification.



Takaro’s tiles are equipped with high sample-rate multi-touch and proximity sensors, together with directional sensors for tile configuration detection and smart adjustment to exergame activities.

The system is versatile and modular (surface size, configuration, placed on a floor, a table, or a wall). Platform size varies from 2 tiles up to 9 tiles (1.5 meter squared) or even the combination of several platforms to cover any floor size.

The Qni is an open platform that supports a popular game development framework. We provide an SDK and a simulator for the developers’ community, enabling the rapid development of activities and games.

Takaro has applied for 30 patents (in varied registration stages) protecting our innovative knowhow.

High Level Plan and Major Milestones

Takaro Tech will initially target the senior market. A pilot project is planned for Q3/21 together with the “Healthy Aging” organization. The goal is to reach a beta product for the senior market during Q4/21 with commercial product availability planned for Q1/22.

In parallel, Takaro will commence a clinical trial with the ALYN Paediatric and Adolescent Rehabilitation Hospital during Q3/21. The goal is to reach a rehabilitation beta product in Q1/22 with commercial availability for rehabilitation institutes and clinics by Q3/22.

High Level Plan

QNI™ adaptive trainer (elderly)



QNI™ rehabilitation trainer



Use of Proceeds

1. **R&D**

Working towards a commercial product, Takaro will complete its beta product for performing the pilot in the elderly market, and progress to a commercial product ready for market penetration and sales in the senior market during Q1/22. In parallel, progress with the requirements and the development of the rehabilitation beta product toward Q1/22.

2. **Product Manufacturing**

Finalize the senior-market product file, ready to scale Qni manufacturing together with an assembly/manufacturing plant. The goal is to manufacture the Qni product batch for the local market.

3. **Israel as BETA Site**


Penetrate the local (Israeli) market with the Qni for the elderly. Perform pilot that will lead product sales within the leading elderly's assisted living facilities. In parallel commence the rehabilitation product clinical trials with ALYN hospital and Loewenstein hospital.

4. **Marketing & Sales**

Prepare marketing materials and sales toolkit for the elderly market. Commence penetration and business development activities within the selected territory.

5. **Investment round A**

Prepare and execute Takaro's investment round A roadshow. The goal is to reach investment round closure within Q1/22.



Forward-Looking Statements

Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.